▲ +77.45% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is $15.38, with a high forecast of $26.00 and a low forecast of $10.00. The average price target represents a 77.45% upside from the last price of $8.67.
The current consensus among 12 polled investment analysts is to buy stock in Voyager Therapeutics. This rating has held steady since November 2020, when it changed from a Hold consensus rating.
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.